Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma

NCT05600686 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Double-Expressor Lymphoma
High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements
High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements

Interventions

DRUG: Cyclophosphamide
DRUG: Doxorubicin
DRUG: Etoposide
BIOLOGICAL: Loncastuximab Tesirine
DRUG: Prednisone
BIOLOGICAL: Rituximab
DRUG: Vincristine

Sponsor

Joseph Tuscano

Collaborators

[object Object]
[object Object]